{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:31:47Z","timestamp":1790303507244,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1124\/dmd.117.077818","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:30:27Z","timestamp":1507768227000},"page":"1354-1363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity"],"prefix":"10.1016","volume":"45","author":[{"given":"Hui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunsheng","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.077818_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7861\/clinmedicine.17-1-54","article-title":"Gout\u2014a guide for the general and acute physicians","volume":"17","author":"Abhishek","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"10.1124\/dmd.117.077818_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/jpet.115.231647","article-title":"Stronger uricosuric effects of the novel selective URAT1 inhibitor UR-1102 lowered plasma urate in tufted capuchin monkeys to a greater extent than benzbomarone","volume":"357","author":"Ahn","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.077818_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1046\/j.1440-1746.2002.02692.x","article-title":"Fulminant hepatic failure associated with benzbromarone treatment: a case report","volume":"17","author":"Arai","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.117.077818_bib4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.steroids.2015.10.008","article-title":"Synthesis of A-ring halogenated 13\u03b1-estrone derivatives as potential 17\u03b2-HSD1 inhibitors","volume":"104","author":"Bacsa","year":"2015","journal-title":"Steroids"},{"key":"10.1124\/dmd.117.077818_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1742-1241.2009.02188.x","article-title":"Update on gout and hyperuricemia","volume":"64","author":"Baker","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1124\/dmd.117.077818_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dmpk.2016.10.412","article-title":"Identification of novel glutathione adducts of benzbromarone in human liver microsomes","volume":"32","author":"Cho","year":"2017","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.117.077818_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1124\/dmd.117.077818_bib9","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1021\/acs.chemrestox.6b00250","article-title":"Different reactive metabolites of nevirapine require distinct glutathione S-transferase isoforms for bioinactivation","volume":"29","author":"Dekker","year":"2016","journal-title":"Chem Res Toxicol"},{"issue":"Suppl 2","key":"10.1124\/dmd.117.077818_bib10","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/rheumatology\/kep086","article-title":"New insights into the epidemiology of gout","volume":"48","author":"Doherty","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/dmd.117.077818_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.rbr.2016.03.006","article-title":"Relevant aspects of imaging in the diagnosis and management of gout","volume":"57","author":"Fernandes","year":"2017","journal-title":"Rev Bras Reumatol"},{"key":"10.1124\/dmd.117.077818_bib12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1021\/acs.jmedchem.5b00997","article-title":"Computational tools to model halogen bonds in medicinal chemistry","volume":"59","author":"Ford","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.077818_bib13","first-page":"39","article-title":"Effects of orange juice and hesperetin on serum paraoxonase activity and lipid profile in hyperuricemic rats","volume":"2","author":"Haidari","year":"2012","journal-title":"Bioimpacts"},{"key":"10.1124\/dmd.117.077818_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/138945010790711996","article-title":"Halogen atoms in the modern medicinal chemistry: hints for the drug design","volume":"11","author":"Hernandes","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1124\/dmd.117.077818_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-016-0579-7","article-title":"New and pipeline drugs for gout","volume":"18","author":"Keenan","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1124\/dmd.117.077818_bib17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1124\/dmd.115.065037","article-title":"Novel bioactivation pathway of benzbromarone mediated by cytochrome P450","volume":"43","author":"Kitagawara","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.077818_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0254-6272(16)30028-0","article-title":"Uric acid lowering effect of Tibetan medicine RuPeng15 powder in animal models of hyperuricemia","volume":"36","author":"Kou","year":"2016","journal-title":"J Tradit Chin Med"},{"key":"10.1124\/dmd.117.077818_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010457.pub2","article-title":"Uricosuric medications for chronic gout","author":"Kydd","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/dmd.117.077818_bib20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"10.1124\/dmd.117.077818_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/03602532.2011.605791","article-title":"Metabolic activation in drug-induced liver injury","volume":"44","author":"Leung","year":"2012","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.117.077818_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1124\/dmd.106.014100","article-title":"Deacetylclivorine: a gender-selective metabolite of clivorine formed in female Sprague-Dawley rat liver microsomes","volume":"35","author":"Lin","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.077818_bib23","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1039\/b926326h","article-title":"Nonbonding interactions of organic halogens in biological systems: implications for drug discovery and biomolecular design","volume":"12","author":"Lu","year":"2010","journal-title":"Phys Chem Chem Phys"},{"key":"10.1124\/dmd.117.077818_bib24","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1021\/tx7001228","article-title":"Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate","volume":"20","author":"McDonald","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.117.077818_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/17425255.2015.1020295","article-title":"Recent advances in fluorination techniques and their anticipated impact on drug metabolism and toxicity","volume":"11","author":"Murphy","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.117.077818_bib26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1124\/dmd.116.069310","article-title":"Biosynthesis of fluorinated analogs of drugs using human cytochrome P450 enzymes followed by deoxyfluorination and quantitative nuclear magnetic resonance spectroscopy to improve metabolic stability","volume":"44","author":"Obach","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.077818_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jbt.20005","article-title":"Differential oxidant potential of carcinogenic and weakly carcinogenic estrogens: involvement of metabolic activation and cytochrome P450","volume":"18","author":"Patel","year":"2004","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/dmd.117.077818_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12325-014-0175-z","article-title":"A review of uric acid, crystal deposition disease, and gout","volume":"32","author":"Perez-Ruiz","year":"2015","journal-title":"Adv Ther"},{"key":"10.1124\/dmd.117.077818_bib29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1039\/B610213C","article-title":"Fluorine in medicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem Soc Rev"},{"key":"10.1124\/dmd.117.077818_bib31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/jm970701f","article-title":"Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption","volume":"41","author":"Rosenblum","year":"1998","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.077818_bib32","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/00325481.2016.1221732","article-title":"Overview of serum uric acid treatment targets in gout: why less than 6 mg\/dL?","volume":"128","author":"Ruoff","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1124\/dmd.117.077818_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0022-1139(01)00375-X","article-title":"Fluorine substituent effects (on bioactivity)","volume":"109","author":"Smart","year":"2001","journal-title":"J Fluor Chem"},{"key":"10.1124\/dmd.117.077818_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.berh.2010.10.004","article-title":"Epidemiology of gout: an update","volume":"24","author":"Smith","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1124\/dmd.117.077818_bib36","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1021\/acs.chemrestox.6b00275","article-title":"Cysteine-based protein adduction by epoxide-derived metabolite(s) of benzbromarone","volume":"29","author":"Wang","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.117.077818_bib37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1124\/dmd.115.066803","article-title":"Identification of epoxide-derived metabolite(s) of benzbromarone","volume":"44","author":"Wang","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 2","key":"10.1124\/dmd.117.077818_bib38","first-page":"S223","article-title":"Tradescantia albiflora Kunth extracts reduce serum uric acid levels in oxonate-induced rats","volume":"12","author":"Wang","year":"2016","journal-title":"Pharmacogn Mag"},{"key":"10.1124\/dmd.117.077818_bib39","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1021\/jm1015022","article-title":"Developing potent human uric acid transporter 1 (hURAT1) inhibitors","volume":"54","author":"Wempe","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.077818_bib40","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1021\/jm3012068","article-title":"Principles and applications of halogen bonding in medicinal chemistry and chemical biology","volume":"56","author":"Wilcken","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.077818_bib41","doi-asserted-by":"crossref","unstructured":"Wu T, Chen JS, Dong S, Li HS, Cao Y, Tian YX, Fu WM, Zhou PZ, Xi BM, Pang JX (2017) Identification and characterization of a potent and selective inhibitor of human urate transporter 1. Pharmacol Rep, in press.","DOI":"10.1016\/j.pharep.2017.04.022"},{"key":"10.1124\/dmd.117.077818_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci400539q","article-title":"Halogen bond: its role beyond drug-target binding affinity for drug discovery and development","volume":"54","author":"Xu","year":"2014","journal-title":"J Chem Inf Model"},{"key":"10.1124\/dmd.117.077818_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cbi.2015.10.009","article-title":"Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity","volume":"255","author":"Xuan","year":"2016","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.117.077818_bib44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/rcm.7148","article-title":"Mass spectrometry based detection of glutathione with sensitivity for single-cell analysis","volume":"29","author":"Yu","year":"2015","journal-title":"Rapid Commun Mass Spectrom"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.077818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:33:29Z","timestamp":1739903609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624054485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0090955624054485"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.077818","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.077818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}